281 related articles for article (PubMed ID: 24582568)
1. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
2. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
3. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
4. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease.
Beaugerie L; Svrcek M; Seksik P; Bouvier AM; Simon T; Allez M; Brixi H; Gornet JM; Altwegg R; Beau P; Duclos B; Bourreille A; Faivre J; Peyrin-Biroulet L; Fléjou JF; Carrat F;
Gastroenterology; 2013 Jul; 145(1):166-175.e8. PubMed ID: 23541909
[TBL] [Abstract][Full Text] [Related]
5. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.
Sokol H; Beaugerie L; Maynadié M; Laharie D; Dupas JL; Flourié B; Lerebours E; Peyrin-Biroulet L; Allez M; Simon T; Carrat F; Brousse N;
Inflamm Bowel Dis; 2012 Nov; 18(11):2063-71. PubMed ID: 22271569
[TBL] [Abstract][Full Text] [Related]
6. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
7. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
8. Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors.
Deepak P; Stobaugh DJ
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1857-8. PubMed ID: 25158928
[No Abstract] [Full Text] [Related]
9. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.
Beaugerie L; Carrat F; Nahon S; Zeitoun JD; Sabaté JM; Peyrin-Biroulet L; Colombel JF; Allez M; Fléjou JF; Kirchgesner J; Svrcek M;
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):892-899.e2. PubMed ID: 29199142
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Beaugerie L; Brousse N; Bouvier AM; Colombel JF; Lémann M; Cosnes J; Hébuterne X; Cortot A; Bouhnik Y; Gendre JP; Simon T; Maynadié M; Hermine O; Faivre J; Carrat F;
Lancet; 2009 Nov; 374(9701):1617-25. PubMed ID: 19837455
[TBL] [Abstract][Full Text] [Related]
11. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
Lopez A; Beaugerie L; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2014 Dec; 10(12):1563-5. PubMed ID: 25362886
[TBL] [Abstract][Full Text] [Related]
12. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients With Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk.
Khan N; Patel D; Trivedi C; Kavani H; Pernes T; Medvedeva E; Lewis J; Xie D; Yang YX
Am J Gastroenterol; 2021 Apr; 116(4):741-747. PubMed ID: 33982944
[TBL] [Abstract][Full Text] [Related]
14. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
15. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
Coelho J; Beaugerie L; Colombel JF; Hébuterne X; Lerebours E; Lémann M; Baumer P; Cosnes J; Bourreille A; Gendre JP; Seksik P; Blain A; Metman EH; Nisard A; Cadiot G; Veyrac M; Coffin B; Dray X; Carrat F; Marteau P;
Gut; 2011 Feb; 60(2):198-203. PubMed ID: 21115547
[TBL] [Abstract][Full Text] [Related]
17. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.
Wisniewski A; Kirchgesner J; Seksik P; Landman C; Bourrier A; Nion-Larmurier I; Marteau P; Cosnes J; Sokol H; Beaugerie L;
United European Gastroenterol J; 2020 Apr; 8(3):303-313. PubMed ID: 32529821
[TBL] [Abstract][Full Text] [Related]
18. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
19. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
20. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]